TrialsgrambetaRCTs are beautiful

Hypertension & pregnancy

Blood-pressure targets, drug classes, renal denervation and hypertensive disorders of pregnancy.

  • 2025BPROAD⁠BP targetIn 12,821 patients with type 2 diabetes, intensive blood-pressure control to below 120 mm Hg reduced major cardiovascular events compared with a target below 140 mm Hg.HR 0.79Read →
  • 2023SPYRAL HTN-ON MED⁠Renal denervationIn 337 patients with uncontrolled hypertension on 1-3 antihypertensive drugs, radiofrequency renal denervation did not significantly lower 24-hour ambulatory systolic blood pressure at 6 months versus a sham procedure (-1.9 mmHg, 95% CI -4.4 to 0.5).Read →
  • 2022CHAP Core⁠Hypertension in pregnancyIn 2,408 pregnant women with mild chronic hypertension, antihypertensive treatment targeting a blood pressure below 140/90 mmHg reduced severe pre-eclampsia, medically indicated preterm birth, placental abruption or fetal or neonatal death compared with treatment withheld unless blood pressure reached 160/105 mmHg.RR 0.8295% CI 0.74-0.92Read →
  • 2017ASPRE⁠Pre-eclampsia preventionIn 1,776 women with singleton pregnancies at high risk of preterm pre-eclampsia on first-trimester screening, aspirin 150 mg daily from 11–14 until 36 weeks reduced delivery with pre-eclampsia before 37 weeks compared with placebo.OR 0.3895% CI 0.20-0.74Read →
  • 2015SPRINT Core⁠BP targetIn 9,361 high-risk non-diabetic hypertensive adults, intensive BP control to SBP < 120 mm Hg reduced CV events and all-cause mortality compared with standard control to SBP < 140 mm Hg.HR 0.75Read →
  • 2015CHIPS⁠Hypertension in pregnancyIn 987 pregnant women with non-proteinuric pre-existing or gestational hypertension, less-tight blood-pressure control did not reduce pregnancy loss or high-level neonatal care compared with tight control targeting a diastolic pressure of 85 mmHg, but led to far more severe maternal hypertension.OR 1.0295% CI 0.77-1.35Read →
  • 2015PATHWAY-2⁠MRAIn 335 patients with drug-resistant hypertension, add-on spironolactone lowered home systolic blood pressure more than placebo, bisoprolol, or doxazosin.Read →
  • 2014SYMPLICITY HTN-3⁠Renal denervationIn 535 patients with resistant hypertension, catheter-based renal denervation did not lower office systolic blood pressure compared with a sham procedure.Read →
  • 2008ACCOMPLISH⁠Drug classIn 11,506 high-risk patients with hypertension, an ACE inhibitor plus amlodipine reduced cardiovascular events compared with an ACE inhibitor plus hydrochlorothiazide.HR 0.8Read →
  • 2008HYVET⁠ElderlyIn 3,845 patients with hypertension aged 80 or older, antihypertensive treatment reduced stroke and all-cause mortality compared with placebo.Read →
  • 2002ALLHAT⁠Drug classIn 33,357 hypertensive patients ≥ 55 with ≥ 1 CV risk factor, chlorthalidone was at least as effective as amlodipine or lisinopril for preventing fatal CHD or non-fatal MI.Read →
  • 2002MAGPIE Core⁠Eclampsia preventionIn 10,141 women with pre-eclampsia before delivery or shortly afterwards, magnesium sulphate halved the risk of eclamptic convulsions compared with placebo, without reducing perinatal death.0.8% vs 1.9%Read →